Centogene N.V. (NasdaqGM:CNTG) (the ?Company?) announced that the Company has decided to explore a range of strategic alternatives focused on sustainable long-term value creation for the benefit of its stakeholders. ?The Supervisory Board supports exploring strategic alternatives to unlock value for CENTOGENE's stakeholders, in a due process and in observance of good governance,? said Peer Schatz, Chairman of the Supervisory Board of CENTOGENE.

?CENTOGENE remains committed to its important and very critical mission: to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.? The Supervisory Board has appointed a special committee, consisting of independent members, to oversee the exploration and evaluation of potential strategic alternatives, and has engaged an advisory firm to support in the process. Strategic alternatives may include, without limitation, an acquisition of CENTOGENE through a tender offer, a merger or other business combination, divestitures of asset, licensing/partnership transactions, seeking additional financing, and/or continuing to operate as an independent public company.

There can be no assurance that the Company?s strategic review process will result in any transaction or other strategic outcome. There is no set timetable for this process. CENTOGENE does not intend to disclose further developments on this strategic review process unless and until it determines that such disclosure is appropriate or necessary.